National Government Services Inc., which processes Medicare and Medicaid claims for the federal government, attributed the job reductions to the loss of a government contract. The subsidiary will still have about 500 workers in Indianapolis.
The merger of Kokomo’s Howard Regional Health System into Indianapolis-based Community Health Network received final approval Tuesday night.
Since its acquisition last year by Florida-based AssuredPartners Inc., the Indiana operations of Neace Lukens has been looking more aggressively to acquire smaller benefits brokers. In the past month, Neace Lukens has announced deals to buy Benefit Concepts, a six-person benefits consultancy in Indianapolis, and Matrix Benefits and Consulting Group, a one-person benefits shop in Fort Wayne. Eric Chelovitz, managing director of Neace Lukens’ 34-person Indianapolis office, said he expects more consolidation in the industry.
Indiana University Health will refund the federal Medicare program $280,000 after an audit of almost 200 claims made by its downtown hospitals found nearly 18 percent of them had been billed improperly.
Most analysts agree with Eli Lilly and Co.’s prediction that, after tough years from 2012 to 2014, the drugmaker will begin growing sales and profits again. But in a new report, BMO Capital Markets predicts Lilly will get stuck at a reduced level of revenue and profit in 2014 and stay there for years.
Johnson & Johnson and Bayer AG’s blood-thinner Xarelto should be approved to help prevent heart attacks and strokes in patients with a common condition, a U.S. regulatory report recommended.
Raising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
Eli Lilly and other big pharmaceutical companies are creating thousands of research jobs overseas as countries led by Singapore, Ireland and South Africa boost incentives.
Indianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection Thursday.
The proposal, which sought twice-yearly reports on all the health insurer’s donations used for political campaigns or lobbying, was overwhelmingly voted down by WellPoint shareholders.
A mix of union groups, activist investors and single-payer advocates will call for increased disclosure from WellPoint, and some investment funds will vote against WellPoint board members who they say have failed to exercise proper oversight of WellPoint’s political spending.
Much of the nearly 45 minutes of arguments and questioning on May 10 involved the justices and the lawyers for both parties trying unsuccessfully to apply various scenarios from the retail world of commerce to health care pricing.
Indiana has taken “a giant step backward” in the availability of early-stage capital for life sciences companies, according to the Indiana Health Industry Forum—which also has a few ideas on how to reverse those developments.
Treatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs that attack the same protein as Roche’s experimental drug.
Purdue University's trustees approved plans Friday for a new campus medical clinic that administrators expect eventually will cut the school's health care costs for employees and their families.
Myth prevents policymakers from attacking real problem of distributing funding.
Boom in elderly population and falling reimbursements expected to cause squeeze.
But major Indianapolis-area hospitals still prefer personal referrals
A second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing a similar drug.
For more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward the drugmaker’s diabetes portfolio.
